Evaluation of cardiac uptake during a PET examination 18F Flutematamol (Vizamyl®) in cardiac damage amyloid.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2013-003911-23-FR

Enrollment

Registered

2015-09-16

Start date

2016-10-14

Completion date

Unknown

Last updated

2020-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Trade Name: VIZAMYL 400 MBq/mL solution injectable Product Name: flutémétamol (18F) Pharmaceutical Form: Injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 15 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 15

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: Assessing myocardial uptake of 18F-flutemetamol (Vizamyl®) in patients with cardiac amyloid reached.;Secondary Objective: ;Primary end point(s):	—

Countries

France

Contacts

Public ContactAmandine pauze

CHU Toulouse

pauze.a@chu-toulouse.fr05 61 77 84 3433

Outcome results